FI67371B - Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner - Google Patents

Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner Download PDF

Info

Publication number
FI67371B
FI67371B FI814080A FI814080A FI67371B FI 67371 B FI67371 B FI 67371B FI 814080 A FI814080 A FI 814080A FI 814080 A FI814080 A FI 814080A FI 67371 B FI67371 B FI 67371B
Authority
FI
Finland
Prior art keywords
compound
group
formula
carbon atoms
hcl
Prior art date
Application number
FI814080A
Other languages
English (en)
Finnish (fi)
Other versions
FI67371C (fi
FI814080L (fi
Inventor
Folke Lars-Erik Arvidsson
Per Arvid Emil Carlsson
Uli Alf Hacksell
John Stephan Mikael Hjorth
Per Lennart Lindberg
John Lars Gunnar Nilsson
Domingo Sanchez
Nils Uno Eimer Svensson
Haokan Vilhelm Wikstroem
Original Assignee
Astra Laekemedel Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab
Publication of FI814080L publication Critical patent/FI814080L/fi
Priority to FI831681A priority Critical patent/FI831681A0/fi
Publication of FI67371B publication Critical patent/FI67371B/fi
Application granted granted Critical
Publication of FI67371C publication Critical patent/FI67371C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (6)

1. Förfarande för framstä11ning av en farmakologiskt aktiv förening med forme In Y r '-(CH.J 2 n dar n är 1 eller 2, Y är OH, R^OO-, R2R3I\ICCG- eller R40, varvid R^ är en alkylgrupp med 1-5 kolatomer, en fenyl-, 2,6-dimetylfe ny 1- eller 3- eller 4-hydroxifenyIgrupp eller en 3- eller 4 - a 1kanoy1oxife nyIgrupp med formeln 5 2 oär R' är en alkylgrupp med 1-5 kolatomer, R är en alkylgrupp med 1-5 kolatomer, en fenyletyl-, bensyl- eller fenyl" 3 grupp, R är H eller en alkylgrupp med 1-5 kolatomer, Λ F; är en allyl- eller bensylgrupp ooh R är en alkylgrupp med 1-5 kolatomer, en hydroxiai ky 1-, dimetylaminoalky 1-eller mety11ioa1 ky 1grupp med 2-5 kolatomer i alkyldelen ooh med heteroatomen bunden i annan position än 1-ställning eller en annan alkenylgrupp med 3-5 kolatomer än 1-alkenyl, sasom bas eller farmaceutiskt acceptabelt syraadditionssalt därav, kännetecknat av att a) en eter eller ester med formeln Ra0 6rv 98 67371 väri Rö representerar en kolväte- eller acylrest, och n och R är som definierats ovan, spaltas for att bilda en förening enligt formel I där Y är en hydroxigrupp, eller b) i en förening enligt formeln Z *- ( CH., ) ^ n väri Z representerar SO^H, Cl eller och n och R är som definierats ovan, gruppen Z ersättes med en hydroxigrupp tij1 bildning av en förening enligt formel I där Y representerar en hydroxigrupp, eller c) en förening enligt formel I Y | rr (CH^)n väri Y är OH och R är annat an hydroxialkyl och som ytter- ligare definierats ovan, och n är som definierats ovan, omvandlas tili en förening enligt samma formel, väri Y är R^COO- eller R2RJNC00- eller R40, där R1, R2, R3 och R4 är som definierats ovan, genom att behandla den förstnämnda föreningen med en lämplig karboxylsyrahalid R^COX eller -anhydrid (R^C0)_,0 eller med en lämplig karbamoylhalid 2 3 ^ 2 R R NCOX eller isocyanat R NCO, i närvaro av en bas eller 4 syra, eller med en passande allyl- eller bensylhalid R X närvaro av en bas, varvid X betecknar en halogen, eller 99 6 7 3 71 d) en förening enligt formel 0ur 1 -‘k’n väri n och Y är som definierats ovan, omvandlas tili en förening enligt formel I genom alkylering av kväveatomen med ett lämpligt alkyleringsmedel, eller e) en amid- eller imidinnehällande förening enligt formeln R^(j) OI IV C (CH_)—ΓΓ 2 n 1 2 väri M och M är lika eller olika och vardera represen- terar -CH0- eller __C = 0, och M är -C-Ru när bSde M och
2 II 0 n2 är -CH2-/ och i andra fall PV3 Mr R, och Rc är H, en alkylgrupp eller alkoxylgrupp som innehäller 1-4 kolatomer, en hydroxialkyl-, dimetylaminoalkyl- eller metyltioalkyl-grupp som innehäller 1-5 kolatomer eller en alkenylgrupp med 2-4 kolatomer, och R1"* är H, R^CO, allyl eller bensyl, och R och R^ är som definierats ovan, omvandlas tili en förening enligt formeln I där Y är en hydroxi, allyloxi^-eller bensyloxig^Tiqpp,, genom reduktion av amid- eller imid-funktionen och esterfunktionen R^COO om den är närvarande, eller 100 6 7 3 71 f) en förening enligt formeln Y1 f VI1 väri Y är bensyloxi eller Y, varvid Y är som definierats ovan emellertid annat än O-allyl, och R är en alkylgrupp som innehäller 1-5 kolatomer eller en hydroxialkyl-, di- metylaminoalkyl- eller metyltioalkylgrupp med 2-6 kolatomer och som har heteroatomen bunden i en annan position än 1- positionen, omvandlas genom reduktion tili motsvarande förening enligt fcrmel I där n är 2, varvid när Y är ben-syloxi en förening enligt formel I där Y är OH erhälles, varefter eventuellt en bas som erhällits omvandlas tili ett farmaceutiskt acceptabelt. syraadditionssalt eller ett er-hället sait omvandlas tili basen eller tili ett annat far-maceutiskt acceptabelt syraadditionssalt, och eventuellt en erhällen isomerisk blandning separeras tili en ren isomer.
FI814080A 1979-12-05 1981-12-18 Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner FI67371C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI831681A FI831681A0 (fi) 1979-12-05 1983-05-13 Nya foereningar som aer anvaendbara som mellanprodukter vid framstaellning av farmakologiskt aktivafenyl-azacyklo-alkaner

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE7910026 1979-12-05
SE7910026 1979-12-05
SE8000319 1980-12-05
PCT/SE1980/000319 WO1981001552A1 (en) 1979-12-05 1980-12-05 New phenyl-azacycloalkanes

Publications (3)

Publication Number Publication Date
FI814080L FI814080L (fi) 1981-12-18
FI67371B true FI67371B (fi) 1984-11-30
FI67371C FI67371C (fi) 1985-03-11

Family

ID=20339477

Family Applications (1)

Application Number Title Priority Date Filing Date
FI814080A FI67371C (fi) 1979-12-05 1981-12-18 Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner

Country Status (17)

Country Link
US (1) US4426386A (sv)
EP (2) EP0030526B1 (sv)
JP (1) JPS6135175B2 (sv)
AT (1) ATE42281T1 (sv)
AU (1) AU542153B2 (sv)
CA (1) CA1147339A (sv)
DD (1) DD155065A5 (sv)
DE (1) DE3070247D1 (sv)
DK (1) DK155793C (sv)
ES (3) ES8205768A1 (sv)
FI (1) FI67371C (sv)
GR (1) GR72841B (sv)
HU (1) HU185422B (sv)
IE (1) IE50674B1 (sv)
PT (1) PT72172B (sv)
SE (1) SE8107742L (sv)
WO (1) WO1981001552A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446335B (sv) * 1982-03-30 1986-09-01 Astra Laekemedel Ab Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin
SE8305362D0 (sv) * 1983-09-30 1983-09-30 Astra Laekemedel Ab Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
US4937346A (en) * 1979-12-05 1990-06-26 Per Arvid Emil Carlsson Phenyl-azacykloalkanes
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
US4719219A (en) * 1982-03-30 1988-01-12 Per A. E. Carlsson Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
ATE36153T1 (de) * 1982-10-01 1988-08-15 Hoffmann La Roche Spaltung von rac. 1-propyl-3-aryl-piperidinen.
US4593037A (en) * 1984-07-26 1986-06-03 Pfizer Inc. 1,3-disubstituted piperidine compounds as neuroleptic agents
JPH0657695B2 (ja) * 1985-07-12 1994-08-03 エーザイ株式会社 ４−シアノピペリジン誘導体
US4826869A (en) * 1988-02-19 1989-05-02 Syntex (U.S.A.) Inc. N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines
DE3930282A1 (de) * 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
SE9802546D0 (sv) * 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia
NZ514560A (en) * 1999-03-31 2004-02-27 Univ Arizona Foundation Viral treatment
US7346938B2 (en) * 2002-08-02 2008-03-25 Roy W. Mattson, Jr. Retrofit suction sanitation safety cover
EP1707558A1 (en) * 2005-03-21 2006-10-04 Ferrer Internacional, S.A. Benzoic acid ester compounds, compositions, uses and methods related thereto

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2892842A (en) 1959-06-30 Their preparation
CH372667A (de) * 1957-09-26 1963-10-31 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
FR1248129A (fr) * 1959-02-12 1960-12-09 Mead Johnson & Co Procédé de préparation des 1-acyl- et 1-carbalkoxy-3 pyrrolidinols
US2975193A (en) * 1959-06-18 1961-03-14 Parke Davis & Co Organic amine compounds and method of obtaining the same
NO116115B (sv) * 1962-06-01 1969-02-03 Parke Davis & Co
DK104736C (da) * 1962-06-20 1966-06-27 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidin-derivater eller syreadditionssalte deraf.
DK104980C (da) * 1962-06-20 1966-08-01 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske 1-methylpyrrolidinderivater eller syreadditionssalte deraf.
DK105337C (da) * 1962-06-20 1966-09-19 Parke Davis & Company A Corp O Fremgangsmåde til fremstilling af optisk aktive eller racemiske pyrrolidinforbindelser eller syreadditionssalte deraf.
DE1470155A1 (de) * 1963-04-11 1969-06-04 Parke Davis & Co Neue Pyrrolidinverbindungen,ihre Saeureadditionssalze,sowie Verfahren zu deren Herstellung
GB1012008A (en) * 1963-08-01 1965-12-01 Parke Davis & Co Process for the production of pyrrolidine compounds
GB1198973A (en) 1969-02-07 1970-07-15 Parke Davis & Co Pyrrolidine Compounds with an Unsaturated Substituent and Methods for their Production
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
CH526536A (de) 1970-02-05 1972-08-15 Sandoz Ag Verfahren zur Herstellung neuer 3-Phenylpyrrolidinderivate
GB1283452A (en) * 1970-07-24 1972-07-26 Parke Davis & Co Substituted 1,3-dialkylpyrrolidines and processes for their production
US3970656A (en) * 1974-06-11 1976-07-20 Government Of The United States 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines
FR2310761A1 (fr) 1975-05-16 1976-12-10 Roussel Uclaf Nouveaux derives de la phenyl-piperidine et leurs sels, procede de preparation et application a titre de medicaments
FR2310762A1 (fr) 1975-05-16 1976-12-10 Roussel Uclaf Nouveaux derives n-substitues de la phenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments
DE2701705A1 (de) * 1976-01-28 1977-08-04 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
FR2340734A1 (fr) * 1976-02-13 1977-09-09 Roussel Uclaf Nouveaux derives de la m-trifluoromethylphenyl piperidine et leurs sels, procede de preparation et application a titre de medicaments
FR2380261A2 (fr) * 1977-02-11 1978-09-08 Roussel Uclaf Nouveaux derives de la m-trifluoromethylphenylpiperidine et leurs sels, procede de preparation et application a titre de medicaments

Also Published As

Publication number Publication date
AU6642681A (en) 1981-06-19
ES8300703A1 (es) 1982-11-01
DE3070247D1 (en) 1985-04-04
US4426386A (en) 1984-01-17
ES508029A0 (es) 1982-11-01
HU185422B (en) 1985-02-28
GR72841B (sv) 1983-12-07
EP0084920B1 (en) 1989-04-19
EP0084920A2 (en) 1983-08-03
ES508030A0 (es) 1982-10-01
ES497489A0 (es) 1982-08-01
IE802545L (en) 1981-06-05
DK155793B (da) 1989-05-16
EP0030526A1 (en) 1981-06-17
FI67371C (fi) 1985-03-11
JPS6135175B2 (sv) 1986-08-12
JPS56501679A (sv) 1981-11-19
PT72172B (en) 1982-07-05
CA1147339A (en) 1983-05-31
AU542153B2 (en) 1985-02-07
SE8107742L (sv) 1981-12-23
EP0030526B1 (en) 1985-02-27
DK155793C (da) 1989-10-02
WO1981001552A1 (en) 1981-06-11
ES8300092A1 (es) 1982-10-01
IE50674B1 (en) 1986-06-11
DD155065A5 (de) 1982-05-12
EP0084920A3 (en) 1985-05-22
PT72172A (en) 1981-01-01
ATE42281T1 (de) 1989-05-15
ES8205768A1 (es) 1982-08-01
FI814080L (fi) 1981-12-18
DK342881A (da) 1981-07-31

Similar Documents

Publication Publication Date Title
FI67371B (fi) Foerfarande foer framstaellning av nya farmakologiskt aktiva fenylazacykloalkaner
Hacksell et al. 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
AU702832B2 (en) Substituted aryl piperazines as neurokinin antagonists
US6534522B2 (en) Subtype-selective NMDA receptor ligands and the use thereof
FI78067B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat och en vid foerfarandet anvaend mellanprodukt.
NO174044B (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt amid-derivat
EP2315746A1 (en) Urea derivatives as antibacterial agents
JPH03503163A (ja) 新規アミン、その使用及び製法
HUE028329T2 (en) 2-Phenylethylamino derivatives acting as calcium and / or sodium channel modulators
JPS6012350B2 (ja) 新規アリ−ルピペリジン誘導体の製造方法
US20050250944A1 (en) Synthesis and uses of synephrine derivatives
EP2521714B1 (en) Aromatic sulfone compounds useful in the treatment of central nervous disorders
DE60309349T2 (de) Propanamine derivate als serotonin und norepinephrin reuptake-inhibitoren
JPH0242058A (ja) Ｎ‐置換３‐ピペリジンカルボン酸またはｎ‐置換３‐ピリジンカルボン酸およびそれらの誘導体
WO2008148799A1 (en) New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
US4719219A (en) Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
NO142395B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydro-1h-azepiner
EP2570409B1 (en) Aralkyl diamine derivatives and uses thereof as antidepressant
NO138804B (no) Analogifremgangsmaater til fremstilling av aminosyrederivater med antidepressiv virkning
US4138482A (en) 3-Cyano-N-(N,N-dimethylaminopropyl)-iminodibenzyl and salts thereof
NO147877B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-oksazepin-derivater
US4937346A (en) Phenyl-azacykloalkanes
DK162214B (da) Analogifremgangsmaade til fremstilling af en ren enantiomer af 3-fenyl-n-n-propylpiperidinderivater
CA2566937A1 (en) Substituted 2,5-diaminomethyl-1h-pyrroles

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: CARLSSON, PER ARVID EMIL